Shares of Teleflex Incorporated (NYSE:TFX) have earned a consensus rating of “Buy” from the ten analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $328.86.
TFX has been the subject of several analyst reports. Needham & Company LLC boosted their target price on CoStar Group from $500.00 to $600.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Barclays boosted their target price on Zimmer Biomet from $113.00 to $117.00 and gave the stock an “underweight” rating in a research note on Monday, April 15th. Zacks Investment Research cut Hess Midstream Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. Raymond James reaffirmed a “market perform” rating and set a C$43.00 price objective on shares of Snc-Lavalin Group in a research report on Wednesday, March 27th. Finally, UBS Group reaffirmed a “hold” rating on shares of Bayerische Motoren Werke in a research report on Friday, March 22nd.
TFX traded down $1.71 on Friday, hitting $334.27. 209,959 shares of the company were exchanged, compared to its average volume of 359,848. Teleflex has a twelve month low of $226.02 and a twelve month high of $337.96. The stock has a market capitalization of $15.32 billion, a P/E ratio of 33.76, a price-to-earnings-growth ratio of 2.20 and a beta of 1.01. The company has a current ratio of 2.27, a quick ratio of 1.41 and a debt-to-equity ratio of 0.85. The business has a 50-day moving average price of $316.59.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Wednesday, May 15th were given a dividend of $0.34 per share. The ex-dividend date was Tuesday, May 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.41%. Teleflex’s dividend payout ratio is currently 13.74%.
In other news, VP Cameron P. Hicks sold 1,500 shares of the business’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $298.14, for a total value of $447,210.00. Following the completion of the sale, the vice president now directly owns 6,876 shares of the company’s stock, valued at approximately $2,050,010.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Benson Smith sold 8,500 shares of the business’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $294.52, for a total value of $2,503,420.00. Following the completion of the sale, the director now directly owns 85,300 shares of the company’s stock, valued at $25,122,556. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,449 shares of company stock valued at $14,398,299. Insiders own 2.36% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Quantamental Technologies LLC purchased a new stake in Teleflex during the 1st quarter valued at approximately $26,000. Meeder Asset Management Inc. purchased a new position in shares of Teleflex during the 1st quarter worth approximately $31,000. Quadrant Capital Group LLC raised its stake in shares of Teleflex by 82.8% during the 1st quarter. Quadrant Capital Group LLC now owns 117 shares of the medical technology company’s stock worth $33,000 after buying an additional 53 shares in the last quarter. Icon Wealth Partners LLC purchased a new position in shares of Teleflex during the 1st quarter worth approximately $37,000. Finally, Financial Gravity Wealth Inc. purchased a new position in shares of Teleflex during the 1st quarter worth approximately $52,000. 91.24% of the stock is owned by institutional investors and hedge funds.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Further Reading: Why Invest in Dividend Achievers?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.